期刊文献+

盐城地区109例肺腺癌患者EGFR基因19、21号外显子突变研究

Research of exons 19 and 21 mutations of epidermal growth factor receptor gene in 109 cases of lung adenocarcinoma in Yancheng area
下载PDF
导出
摘要 目的探讨该地区肺腺癌患者表皮生长因子受体(EGFR)基因19、21号外显子突变情况及其在不同人群中的分布差异。方法收集该院2013年4月至2014年9月109例肺腺癌患者相关标本,应用突变特异性扩增系统-聚合酶链式反应(ARMS-PCR)对标本EGFR基因外显子19、21号进行检测。结果 109例患者中,19、21号外显子突变56例(51.38%),其中19号外显子突变24例(22.02%),21号外显子突变33例(30.28%);男性共59例,突变型19例(32.20%),女性50例,突变型37例(74.00%);大于或等于60岁患者64例,突变型34例(53.13%),小于60岁患者45例,突变型22例(48.89%);男性吸烟者33例,突变型7例(21.21%),非吸烟者25例,突变型12例(48.00%)。结论该地区肺腺癌患者EGFR基因19、21号外显子总突变率较高,21号外显子突变率稍高于19号外显子,但差异无统计学意义(P>0.05);突变类型及突变率与性别、吸烟史相关,与年龄不相关。 Objective To investigate the 19 and 21exon mutation status of the epidermal growth factor receptor(EGFR)gene in the patients with lung adenocarcinoma and its distribution differences among different groups.Methods The related samples in 109 cases of lung adenocarcinoma were collected in our hospital during 2013-2014.The 19 and 21exons of EGFR gene were detected by adopting the ARMS-PCR method.Results Among 119 cases,19and 21 exons mutations were found in 56cases(51.38%),in which 24cases(22.02%)were in exon 19 and 33cases(30.28%)were in exon 21.59 cases were male with 19cases(32.20%)of mutant type and 50 cases were female with 37cases(74.00%)of mutant type;64cases were ≥60years old with 34cases(53.13%)of mutant type,45 cases were〈60years old with 22cases(48.89%)of mutant type;33male cases were smoking with7cases(21.21%)of mutant type and 25 male cases were non-smoking with 12cases(48.00%)of mutant type.Conclusion The 19 and 21exon mutation rate of EGFR gene in the patients with lung adenocarcinoma is higher in this area,the 21 exon mutation rate is slightly higher than that of 19exon;the mutation type and mutation rate are correlated with sex and smoking history,but have no correlation with age.
出处 《国际检验医学杂志》 CAS 2015年第24期3568-3569,共2页 International Journal of Laboratory Medicine
关键词 表皮生长因子受体基因 肺腺癌 突变 epidermal growth factor receptor gene lung adenocarcinoma mutation
  • 相关文献

参考文献12

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006 [J]. CACancer J Clin,2006 ,56(3) : 106-130.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of fourchemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2) :92-98.
  • 3Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J], Cancer,2004f304(5676):1497-1500.
  • 4Sequist LV, Bell DW, Lynch TJ , et al. Molecular predictor of re-sponse to epidermal growth factory receptor antagonist in non-small-cell lung cancer[j]. J Clin Oncol, 2007 ,25(5) : 587-595.
  • 5Mistudomi T,Kosaka T. Biological and clinical implications ofEGFR mutations in lung cancer[J]. J Clifi Oncol, 2006, 11 (3):190-198.
  • 6Dacic S. EGFR assays in lung cancer[J]. Adv Anat Pathol, 2008,15(4):241-247.
  • 7董丹丹,唐源,邹艳,李芳华,曹梅,刘卫平.四川地区肺腺癌中EGFR基因19、21外显子突变研究[J].临床与实验病理学杂志,2011,27(12):1306-1309. 被引量:16
  • 8Huang SF, Liu H P. High frequency of epidermal growth fator re-ceptor mutations with complex pattern in non-small cell lungcancers related to gefitinib responsiveness in Taiwan [J]. ClinCancers Res,2004,10(24) :8195-8203.
  • 9Mu XL,Li LY, Zhang XT, et al. Gefitinib sensitive mutations ofthe epidermal growth factor receptor tyrosine kinase domain inChinese patients with non-small cell lung cancer [J]. Clin CancerRes,2005,11(12):4289-4294.
  • 10董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53

二级参考文献40

  • 1张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 2BaoMingQIN,XiaoCHEN,JingDeZHU,DuanQingPEI.Identification of EGFR kinase domain mutations among lung cancer patients in China:implication for targeted cancer therapy[J].Cell Research,2005,15(3):212-217. 被引量:66
  • 3董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53
  • 4Huang S F,Liu H P,Li L H,et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J].Clin Cancer Res,2004,10(24):8195-203.
  • 5Mu X L,Li L Y,Zhang X T,et al.Gefitinib sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer[J].Clin Cancer Res,2005,11(12):4289-94.
  • 6Lynch T J,Bell D W,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-39.
  • 7Paez J G,Janne P A,Lee J C,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-500.
  • 8Rafael R,Moran T,Queralt C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361(10):958-67.
  • 9Sequist L V,Bell D W,Lynch T J,et al.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J].J Clin Oncol,2007,25(5):587-95.
  • 10Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci,2004,101(36):13306-11.

共引文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部